

Special Issue

Antibody Research in the COVID-19 Pandemic

Message from the Guest Editor

The COVID-19 pandemic shook the world globally with dreadful implications, but also demonstrated an unprecedented collective response to the SARS-CoV-2 infection. To address global public health, this Special Issue will discuss the methods and approaches to illustrate and profile the immune response following infection and vaccination. We would like to invite you to share your work on vaccines and/or infection (both COVID-19 and other diseases), with an emphasis on immune response studies. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- The antibody response following vaccination.
- Immune response following infection.
- Role of number and dosage of vaccination in immune response.
- The safety of vaccines.
- Impact of monovalent vs bivalent vaccines.
- Circulating and emerging SARS-CoV-2 variants.

We look forward to receiving your contributions.

Guest Editor

Dr. Surender Khurana

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/170490

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).